Rhythm Pharmaceuticals Inc (fra:1RV) Share Price

Company Profile

Business description
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
Contact
222 Berkeley Street
12th Floor
BostonMA02116
USA
T: +1 857 264-4280
E: [email protected]
https://www.rhythmtx.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
414

Recommended

Lower consumer spending unlikely to buckle this retail REIT.

Yingqi Tan, CFA | 16 June 2026

Sales growth but lack of margin expansion due to competition.

Johannes Faul, CFA | 15 June 2026

Discounted Aussie shares that offer a tax rebate.

Tyger Fitzpatrick | 14 June 2026

Index	Last price	Change	% Change
All Ordinaries	9,131.30	71.80	0.79%
CAC 40	8,447.27	63.26	0.75%
DAX 40	24,910.41	16.40	0.07%
Dow JONES (US)	52,039.57	368.54	0.71%
FTSE 100	10,494.21	63.59	0.61%
HKSE	24,493.95	348.72	-1.40%
NASDAQ	26,511.03	172.91	-0.65%
Nikkei 225	69,404.50	87.00	0.13%
NZX 50 Index	13,426.13	65.54	0.49%
S&P 500	7,527.38	26.91	-0.36%
S&P/ASX 200	8,917.70	77.30	0.87%
SSE Composite Index	4,091.89	4.58	-0.11%